Aim. The purpose of this study is to report the overall infection control rate and prognostic factors associated with acute, hematogenous and chronic PJIs treated with DAIR. Methods. All DAIR procedures performed at 2 institutions from 2009 to 2018 (n=104) were reviewed and numerous data were recorded, including demographics, preoperative laboratory tests, Charleston Comorbidity Index, surgical information and organism culture results. Treatment success was defined according to the criteria reported by Diaz-Ledezma. A multivariable analysis was utilized to identify prognostic factors associated with treatment and a Kaplan-Meier survival analysis was used to depict infection control rate as a function of time. Results. The overall treatment success rate in the current cohort of patients was 67.3% at a median 38.6 (23.5–90.7) months follow-up. Patients with a duration of infectious symptoms greater than 10 days were more likely to fail (P=0.035, odds ratio 8.492, 95% confidence interval 1.159–62.212). There was no difference among acute, hematogenous and chronic infections in terms of failure rate even when time was considered (p=0.161). Conclusion. With careful patient selection, DAIR is a
Reverse total shoulder arthroplasty (RTSA) has a proven track record as an effective treatment for a variety of rotator cuff deficient conditions. However, glenoid erosion associated with the arthritic component of these conditions can present a challenge for the shoulder arthroplasty surgeon. Options for treatment of glenoid wear include partial reaming with incomplete baseplate seating, bony augmentation using structural or impaction grafting techniques, and augmented baseplates. Augmented components have the advantage of accommodating glenoid deformity with a durable material and also ream less subchondral bone; both of which may offer an advantage over traditional bone grafting. Biomechanical and early clinical studies of augmented glenoid baseplates suggest they are a
